0001090872false00010908722024-02-272024-02-27





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 27, 2024
 
AGILENT TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware001-1540577-0518772
(State or other jurisdiction(Commission(IRS Employer
of incorporation)File Number)Identification No.)
 
5301 Stevens Creek Boulevard, Santa Clara, CA 95051
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code (800) 227-9770
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
TITLE OF EACH CLASSTRADING SYMBOL(S)NAME OF EACH EXCHANGE ON WHICH REGISTERED
COMMON STOCK, $0.01 PAR VALUEANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ 


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 




Item 2.02.              Results of Operations and Financial Condition.
 
The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
 
On February 27, 2024, Agilent Technologies, Inc. (the “Company”) issued its press release announcing financial results for the first fiscal quarter ended January 31, 2024.  A copy of this press release is attached as Exhibit 99.1.
 
The Company provides non-GAAP financial information in order to provide meaningful supplemental information regarding its operational performance and to enhance its investors’ overall understanding of its core current financial performance and its prospects for the future.  The Company believes that its investors benefit from seeing its results “through the eyes” of management in addition to the GAAP presentation.  Management measures segment and enterprise performance using measures such as those that are disclosed in this release.  This information facilitates management’s internal comparisons to the Company’s historical operating results and comparisons to competitors’ operating results.  Non-GAAP information allows for greater transparency to supplemental information used by management in its financial and operations decision making.  Historically, the Company has reported similar non-GAAP information to its investors and believes that the inclusion of comparative numbers provides consistency in its financial reporting.
 
This information is not in accordance with, or an alternative for, generally accepted accounting principles in the United States.  It excludes items, such as restructuring and amortization, that may have a material effect on the Company’s expenses and earnings per share calculated in accordance with GAAP.  Management monitors these items to ensure that expenses are in line with expectations and that the Company's GAAP results are correctly stated but does not use them to measure the ongoing operating performance of the Company.  The non-GAAP information the Company provides may be different from the non-GAAP information provided by other companies.
 
Additional explanation of non-GAAP information is provided in Exhibit 99.1.

Item 9.01.              Financial Statements and Exhibits.
 
(d) Exhibits
 
The following is furnished as an exhibit to this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended:
 
Exhibit No. Description
 Press release announcing financial results for the first fiscal quarter ended January 31, 2024
104 Cover page interactive data file (embedded within the Inline XBRL document)


2



SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 AGILENT TECHNOLOGIES, INC.
  
  
 By:/s/ P. Diana Chiu
 Name:P. Diana Chiu
 Title:Vice President, Interim General Counsel
and Secretary
  
  
  
Date: February 27, 2024 






3



Exhibit 99.1

Agilent Reports First-Quarter Fiscal Year 2024 Financial Results

Revenue and earnings exceed Q1 guidance

Full-year outlook maintained

Highlights

•Revenue of $1.66 billion, down 5.6% reported and 6.4% core(1) from the first quarter of 2023.

•GAAP net income of $348 million; earnings per share (EPS) of $1.18, down 1% from the first quarter of 2023.

•Non-GAAP(2) net income of $380 million; EPS of $1.29, down 6% from the first quarter of 2023.

•Full-year revenue outlook maintained at $6.710 billion to $6.810 billion, representing a range of down 1.8% to 0.3% on a reported basis and down 0.5% to up 1% core(1). Fiscal year 2024 non-GAAP(3) earnings guidance also maintained at a range of $5.44 to $5.55 per share.

•Second-quarter revenue outlook expected at $1.560 billion to $1.590 billion with non-GAAP(3) EPS of $1.17 to $1.20.

SANTA CLARA, Calif., Feb. 27, 2024 — Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the first quarter ended Jan. 31, 2024, a decline of 5.6% reported and 6.4% core(1) compared to the first quarter of 2023.
First-quarter GAAP net income was $348 million, or $1.18 per share. This compares with $352 million, or $1.19 per share, in the first quarter of fiscal year 2023. Non-GAAP(2) net income was $380 million, or $1.29 per share during the quarter, compared with $406 million or $1.37 per share during the first quarter a year ago.
“The Agilent team continued its strong execution in the first quarter, delivering better-than-expected revenue and earnings,” said President and CEO Mike McMullen. “We are well positioned for long-term growth driven by our diversified business and multiple growth drivers. While near term market challenges remain, I continue to be optimistic about our future.”

Financial Highlights

In the first quarter of 2024, Agilent implemented certain changes to its segment reporting structure. Prior period segment information has been recast to reflect these changes. These changes have no impact on Agilent’s consolidated financial statements.


1


Life Sciences and Applied Markets Group
Agilent’s Life Sciences and Applied Markets Group (LSAG) reported first-quarter revenue of $846 million, a decline of 10% reported and 11% core(1) year-over-year. LSAG’s operating margin for the quarter was 27.9%.

Agilent CrossLab Group
The Agilent CrossLab Group (ACG) reported first-quarter revenue of $405 million, an increase of 6% reported and 5% core(1) year-over-year. ACG’s operating margin for the quarter was 30.2%.

Diagnostics and Genomics Group
The Diagnostics and Genomics Group (DGG) reported first-quarter revenue of $407 million, a decrease of 6% reported and 6% core(1) year-over-year. DGG’s operating margin for the quarter was 17.3%.

Full Year 2024 and Second-Quarter Outlook
Full-year revenue outlook is maintained at $6.710 billion to $6.810 billion, representing a range of down 1.8% to 0.3% on a reported basis and down 0.5% to up 1% core(1). Fiscal year 2024 non-GAAP(3) earnings guidance is also maintained with a range of $5.44 to $5.55 per share.
The outlook for second-quarter revenue is expected in the range of $1.560 billion to $1.590 billion, a decline of 9.1% to 7.4% reported and a decline of 8.4% to 6.7% core(1). Second-quarter non-GAAP(3) earnings guidance is expected in the range of $1.17 to $1.20 per share.
The outlook is based on forecasted currency exchange rates.

Conference Call
Agilent’s management will present additional details regarding the company’s first-quarter 2024 financial results on a conference call with investors today at 1:30 p.m. PST. This event will be broadcast live online in listen-only mode. To listen to the webcast, select the “Q1 2024 Agilent Technologies Inc. Earnings Conference Call” link on the Agilent Investor Relations website. The webcast will remain on the company site for 90 days.



2


About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding Agilent’s growth prospects, business, financial results, revenue, and non-GAAP earnings guidance for Q2 and fiscal year 2024 and future amortization of intangibles. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended October 31, 2023. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

(1) Core revenue growth excludes the impact of currency and acquisitions and divestitures within the past 12 months. Core revenue is a non-GAAP measure. Reconciliations between GAAP revenue and core revenue for Q1 fiscal year 2024 are set forth on page 6 of the attached tables along with additional information regarding the use of this non-GAAP measure. Core revenue growth rate as projected for Q2 fiscal year 2024 and full fiscal year 2024 excludes the impact of currency and acquisitions and divestitures within the past 12 months. Most of the excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided for the projection.

(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of restructuring and other related costs, asset impairments, intangibles amortization, transformational
3

initiatives, acquisition and integration costs, net loss on equity securities and change in fair value of contingent consideration. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. A reconciliation between non-GAAP net income and GAAP net income is set forth on page 4 of the attached tables along with additional information regarding the use of this non-GAAP measure.

(3) Non-GAAP earnings per share as projected for Q2 fiscal year 2024 and full fiscal year 2024 exclude primarily the estimated impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs. Agilent also excludes any tax benefits or expenses that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. Most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy and could differ materially. Therefore, no reconciliation to GAAP amounts has been provided. Future amortization of intangibles is expected to be approximately $27 million per quarter.

# # # # #

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Media Contact:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com
4

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY
 
Three Months Ended
January 31,
 20242023
Net revenue$1,658 $1,756 
Costs and expenses:
Cost of products and services750 788 
Research and development128 123 
Selling, general and administrative396 419 
Total costs and expenses1,274 1,330 
Income from operations384 426 
Interest income18 9 
Interest expense(22)(25)
Other income (expense), net23 — 
Income before taxes403 410 
Provision for income taxes55 58 
Net income$348 $352 
Net income per share:
Basic$1.19 $1.19 
Diluted$1.18 $1.19 
Weighted average shares used in computing net income per share:
Basic293296 
Diluted294297 




The preliminary income statement is estimated based on our current information.

1

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share data)
(Unaudited)
PRELIMINARY
January 31,
2024		October 31,
2023
ASSETS 
Current assets: 
Cash and cash equivalents$1,748 $1,590 
Accounts receivable, net1,295 1,291 
Inventory1,033 1,031 
Other current assets262 274 
Total current assets4,338 4,186 
Property, plant and equipment, net1,314 1,270 
Goodwill3,967 3,960 
Other intangible assets, net443 475 
Long-term investments170 164 
Other assets716 708 
Total assets$10,948 $10,763 
LIABILITIES AND EQUITY 
Current liabilities:
Accounts payable$488 $418 
Employee compensation and benefits272 371 
Deferred revenue522 505 
Other accrued liabilities335 309 
Total current liabilities1,617 1,603 
Long-term debt2,555 2,735 
Retirement and post-retirement benefits102 103 
Other long-term liabilities486 477 
Total liabilities4,760 4,918 
Total Equity: 
Stockholders' equity: 
Preferred stock; $0.01 par value; 125,000,000 shares authorized; none issued and outstanding at January 31, 2024 and October 31, 2023— — 
Common stock; $0.01 par value; 2,000,000,000 shares authorized; 293,041,817 shares at January 31, 2024 and 292,123,241 shares at October 31, 2023, issued and outstanding3 3 
Additional paid-in-capital5,440 5,387 
Retained earnings1,061 782 
Accumulated other comprehensive loss(316)(327)
Total stockholders' equity6,188 5,845 
Total liabilities and stockholders' equity$10,948 $10,763 
 


The preliminary balance sheet is estimated based on our current information.
2

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
Three Months Ended
January 31,January 31,
20242023
Cash flows from operating activities:
Net income$348 $352 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization62 67 
Share-based compensation44 44 
Deferred taxes— 4 
Excess and obsolete inventory related charges11 7 
Net (gain) loss on equity securities(3)10 
Asset impairment charges8 — 
Change in fair value of contingent consideration— 1 
Other non-cash (income) expenses, net(6)1 
Changes in assets and liabilities:
Accounts receivable, net10 (5)
Inventory(9)(69)
Accounts payable84 (27)
Employee compensation and benefits(104)(174)
Other assets and liabilities40 85 
Net cash provided by operating activities (a)
485 296 
Cash flows from investing activities:
Payments to acquire property, plant and equipment(90)(76)
Proceeds from sale of equity securities— 4 
Payments to acquire equity securities— (1)
Proceeds from convertible note— 2 
Payments in exchange for convertible note(5)(3)
Payments to acquire businesses and intangible assets, net of cash acquired— (30)
Net cash used in investing activities(95)(104)
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock plans34 35 
Payment of taxes related to net share settlement of equity awards (25)(51)
Payments for repurchase of common stock— (75)
Payments of dividends(69)(67)
Repayments of long-term debt(180)— 
Net proceeds from short-term debt— 203 
Payment for contingent consideration— (62)
Net cash used in financing activities(240)(17)
Effect of exchange rate movements7 22 
Net increase in cash, cash equivalents and restricted cash157 197 
Cash, cash equivalents and restricted cash at beginning of period1,593 1,056 
Cash, cash equivalents and restricted cash at end of period$1,750 $1,253 
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:
   Cash and cash equivalents$1,748 $1,250 
   Restricted cash, included in other assets2 3 
   Total cash, cash equivalents and restricted cash$1,750 $1,253 
(a) Cash payments included in operating activities:
Income tax paid, net of refunds received$24 $17 
Interest payments, net of capitalized interest$14 $15 

The preliminary cash flow is estimated based on our current information.
3

AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY 

Three Months Ended
January 31,
20242023
 Net IncomeDiluted
EPS		Net IncomeDiluted
EPS
GAAP net income$348 $1.18 $352 $1.19 
Non-GAAP adjustments:
Restructuring and other related costs3 0.01 — — 
Asset impairments8 0.03 — — 
Intangible amortization26 0.09 36 0.12 
Transformational initiatives3 0.01 7 0.02 
Acquisition and integration costs2 0.01 2 0.01 
Net loss on equity securities— — 12 0.04 
Change in fair value of contingent consideration— — 1 — 
Other(6)(0.02)3 0.01 
Adjustment for taxes (a)
(4)(0.02)(7)(0.02)
Non-GAAP net income$380 $1.29 $406 $1.37 

(a) The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017. For the three months ended January 31, 2024, management used a non-GAAP effective tax rate of 13.50%. For the three months ended January 31, 2023, management used a non-GAAP effective tax rate of 13.75%.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, net loss on equity securities and change in fair value of contingent consideration.

Restructuring and other related costs include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits, facility-related costs and contract termination fees.

Asset impairments include assets that have been written down to their fair value.

Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.

Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

Net loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.

Change in fair value of contingent consideration represents changes in the fair value estimate of acquisition-related contingent consideration.

Other includes acceleration of share-based compensation expense and certain legal costs and settlements in addition to other miscellaneous adjustments.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.
4

AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY

Quarter-over-Quarter

Life Sciences and Applied Markets Group
 Q1'24Q1'23
Revenue$846 $943 
Gross Margin, %60.2 %61.5 %
Income from Operations$236 $300 
Operating margin, %27.9 %31.8 %

Diagnostics and Genomics Group
 Q1'24Q1'23
Revenue$407 $432 
Gross Margin, %52.8 %52.6 %
Income from Operations$70 $73 
Operating margin, %17.3 %16.9 %
 
Agilent CrossLab Group
 Q1'24Q1'23
Revenue$405 $381 
Gross Margin, %50.5 %48.5 %
Income from Operations$122 $103 
Operating margin, %30.2 %27.0 %



Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.
5

AGILENT TECHNOLOGIES, INC.
RECONCILIATION OF REVENUE BY SEGMENT EXCLUDING
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(In millions)
(Unaudited)
PRELIMINARY
 
Year-over-Year
GAAP
GAAP Revenue by SegmentQ1'24Q1'23Year-over-Year
% Change
Life Sciences and Applied Markets Group$846 $943 (10)%
Diagnostics and Genomics Group407 432 (6)%
Agilent CrossLab Group405 381 6%
Agilent$1,658 $1,756 (6)%
Non-GAAP
(excluding Acquisitions and Divestitures)
Year-over-Year at Constant Currency (a)
Non GAAP Revenue by SegmentQ1'24Q1'23Year-over-Year
% Change		Year-over-Year % ChangePercentage Point Impact from Currency
Current Quarter Currency Impact (b)
Life Sciences and Applied Markets Group $846 $943 (10)%(11)%1 ppt$7 
Diagnostics and Genomics Group407 430 (5)%(6)%1 ppt4 
Agilent CrossLab Group 405 381 6%5%1 ppt5 
Agilent (Core)$1,658 $1,754 (5)%(6)%1 ppt$16 
 
.
We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter, and then using those revised values to calculate the year-over-year percentage change.

(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.
6
v3.24.0.1
Document and Entity Information Document
Feb. 27, 2024
Document and Entity Information [Abstract]  
Entity Central Index Key 0001090872
Title of 12(b) Security COMMON STOCK, $0.01 PAR VALUE
Entity Incorporation, State or Country Code DE
Document Type 8-K
Document Period End Date Feb. 27, 2024
Entity Registrant Name AGILENT TECHNOLOGIES, INC.
Entity Tax Identification Number 001-15405
Entity Tax Identification Number 77-0518772
Entity Address, Address Line One 5301 Stevens Creek Boulevard
Entity Address, City or Town Santa Clara
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95051
City Area Code (800)
Local Phone Number 227-9770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol A
Security Exchange Name NYSE
Amendment Flag false
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Agilent Technologies Charts.
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Agilent Technologies Charts.